Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc. develops novel drugs and specialty active pharmaceutical ingredients. Its small-molecule oncology candidates include the G-quadruplex stabilizer Pidnarulex (CX5461) for breast cancer and other homologous repair deficiency (HRD) or solid tumors with BRCA1/2 mutations, a protein kinase CK2 (casein kinase II) inhibitor, and Silmitasertib (CX4945) for cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. The company also provides technical advice and consulting services. It is based in New Taipei City, Taiwan.